Gossamer Bio Inc (GOSS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Gossamer Bio Inc stock (GOSS) is currently trading at $0.38. Gossamer Bio Inc PS ratio (Price-to-Sales) is 2.04. Analyst consensus price target for GOSS is $3.69. WallStSmart rates GOSS as Sell.
- GOSS PE ratio analysis and historical PE chart
- GOSS PS ratio (Price-to-Sales) history and trend
- GOSS intrinsic value — DCF, Graham Number, EPV models
- GOSS stock price prediction 2025 2026 2027 2028 2029 2030
- GOSS fair value vs current price
- GOSS insider transactions and insider buying
- Is GOSS undervalued or overvalued?
- Gossamer Bio Inc financial analysis — revenue, earnings, cash flow
- GOSS Piotroski F-Score and Altman Z-Score
- GOSS analyst price target and Smart Rating
Gossamer Bio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Gossamer Bio Inc (GOSS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Gossamer Bio Inc (GOSS) Key Strengths (2)
Revenue surging 47.10% year-over-year
74.16% of shares held by major funds and institutions
Supporting Valuation Data
Gossamer Bio Inc (GOSS) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.04x sales
Fairly priced relative to book value
Gossamer Bio Inc (GOSS) Detailed Analysis Report
Overall Assessment
This company scores 35/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 47.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Market Cap. Some valuation metrics including Price/Sales (2.04), Price/Book (2.66) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -783.00%, Operating Margin at -333.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -783.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 47.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GOSS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GOSS's Price-to-Sales ratio of 2.04x sits near its historical average of 2.37x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 23% below its historical high of 2.66x set in Mar 2026, and 0% above its historical low of 2.04x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Gossamer Bio Inc (GOSS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Gossamer Bio Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 48M with 47% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 47% YoY, reaching 48M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 101% of revenue (49M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -48M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Gossamer Bio Inc maintain 47%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.11, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Gossamer Bio Inc.
Bottom Line
Gossamer Bio Inc is a high-conviction growth story with revenue accelerating at 47% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Gossamer Bio Inc(GOSS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.